Recall report: Novo Nordisk recalls samples of multiple insulin products after storage screw-up
Five different insulin drugs have been recalled by Novo Nordisk after the company says the samples were stored at the wrong temperature.
The recall affects 1,468 product samples of Levemir, Tresiba, Fiasp, Novolog and Xultophy. The recall only impacts samples, and not product that’s been distributed to pharmacies or mail-order services, the FDA said.
If samples are exposed to temperatures below 32 degrees Fahrenheit, it could damage the efficacy of the drug and the cartridge and pen-injectors. It that product is used, patients run the risk of not receiving the proper dosage, which could lead to hyperglycemia or hypoglycemia.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.